Compare ZWS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZWS | CYTK |
|---|---|---|
| Founded | 1891 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.0B |
| IPO Year | 2012 | 2004 |
| Metric | ZWS | CYTK |
|---|---|---|
| Price | $46.20 | $63.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 16 |
| Target Price | $47.50 | ★ $84.81 |
| AVG Volume (30 Days) | 1.0M | ★ 1.8M |
| Earning Date | 02-03-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 42.52 | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | ★ $1,659,400,000.00 | $87,211,000.00 |
| Revenue This Year | $8.97 | $341.94 |
| Revenue Next Year | $5.57 | $75.44 |
| P/E Ratio | $42.34 | ★ N/A |
| Revenue Growth | 6.88 | ★ 2609.26 |
| 52 Week Low | $27.74 | $29.31 |
| 52 Week High | $50.03 | $70.98 |
| Indicator | ZWS | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 49.19 |
| Support Level | $45.56 | $62.13 |
| Resistance Level | $48.01 | $65.88 |
| Average True Range (ATR) | 0.98 | 2.59 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 27.52 | 54.84 |
Zurn Elkay Water Solutions Corp designs procures, manufactures, and markets a range of clean water solutions for drinking water, hygiene, and sustainable water management. The company's product portfolio includes professional-grade water control and safety, water distribution and drainage, drinking water, finish plumbing, hygienic, environmental and site works products for public and private spaces.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.